Compare PHAR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | IVA |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Netherlands | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2020 | 2020 |
| Metric | PHAR | IVA |
|---|---|---|
| Price | $11.57 | $4.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $38.33 | $16.20 |
| AVG Volume (30 Days) | 18.0K | ★ 691.2K |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | $751.20 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $3.35 |
| 52 Week High | $21.34 | $7.98 |
| Indicator | PHAR | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 53.04 |
| Support Level | $9.62 | $4.48 |
| Resistance Level | $17.89 | $4.70 |
| Average True Range (ATR) | 0.67 | 0.19 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 58.51 | 54.86 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.